戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 n Hippel-Lindau disease patients (not in the clinical series).
2  frontotemporal lobar degeneration (FTLD) in clinical series.
3 ations were reviewed and limited to original clinical series.
4  in a hybrid as has been observed in several clinical series.
5 pients, ranging between 10% and 50% in large clinical series.
6 nical samples and outcomes reported in large clinical series.
7 as a prospective, single-arm, interventional clinical series.
8  proportions of more than 30% seen in modern clinical series (11 out of 15 studies with a median year
9 les ranged from single case reports to large clinical series and in-depth subject overviews.
10 review evaluates the published case reports, clinical series, and clinical trial data on ocular toxic
11 ACT, a large number of experimental studies, clinical series, and randomized trials have been perform
12  is an apparent synergy, reported in several clinical series, between the initial injuries of ischemi
13                           There are multiple clinical series demonstrating good outcomes from DIC-pos
14                       Recently, in the first clinical series describing the condition, mouse and huma
15                                   This early clinical series explores the safety and efficacy of this
16                         Analysis of extended clinical series found the C9ORF72 repeat expansion to be
17            A critical review of all relevant clinical series from May 2003 to May 2005 was conducted.
18 he results of several industrially sponsored clinical series have been reported recently, all with si
19 w viewed as a neurological illness and large clinical series have clarified the clinical features of
20                                    Worldwide clinical series have documented the efficacy and safety
21                                           In clinical series, high CD8(+) T/T(reg) cell ratios underl
22  have relied on single institution and small clinical series; however, recent population-level analys
23                          Comparing the three clinical series: in the stringently diagnosed Manchester
24                          The purpose of this clinical series is to investigate the presence of biofil
25                                     In small clinical series, loss of 9p21.3, which includes the CDKN
26                                         In a clinical series of 1,124 adult patients with suspected o
27                                   In a first clinical series of 6 patients, cold-stored livers, all a
28                     Prospective, consecutive clinical series of cases.
29                                    The first clinical series of ex situ MP in liver transplantation w
30                    In this first report of a clinical series of simultaneous pancreas-kidney transpla
31 cal diagnosis of Alzheimer disease (AD) in a clinical series of well-characterized AD patients and co
32                     Case reports and limited clinical series over the past 5 years have raised concer
33 the ANKK1 enhancer and PD in two independent clinical series (P = 0.007 and 0.021).
34 s a paucity of objective evidence outside of clinical series published by experienced surgeons that s
35  were found in this community sample than in clinical series studied to date.
36                                   As a large clinical series that explored many of the factors now vi
37                          This is the largest clinical series to date of patients with GDAP1 mutations
38                          Candidates for this clinical series were patients scheduled for a debridemen